Last mentioned: Feb 24, 2026
Expected Finalization
Anticipated period for final guidance after public comment and review.
New System Proposed
FDA formally announces the proposed framework for customized drug approvals.
START Program
CBER launches the Support for clinical Trials Advancing Rare disease Therapeutics pilot.
ASO Guidance
FDA issues initial draft guidance for ASO products for ultra-rare diseases.
The FDA has unveiled a proposed regulatory pathway designed to accelerate the approval of customized, patient-specific therapies for ultra-rare diseases. This initiative aims to shift from traditional population-based clinical trials to a data-driven model that supports individualized genomic medicine.
This page surfaces every story mentioning Rare Disease Patients across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Rare Disease Patients was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |